Voyageur Free Cash Flow Per Share vs Roic Analysis

VM Stock

CAD 0.07 0.01 8.33%

Voyageur Pharmaceuticals financial indicator trend analysis is much more than just breaking down Voyageur Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Voyageur Pharmaceuticals is a good investment. Please check the relationship between Voyageur Pharmaceuticals Free Cash Flow Per Share and its Roic accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Free Cash Flow Per Share vs Roic

Free Cash Flow Per Share vs Roic Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Voyageur Pharmaceuticals Free Cash Flow Per Share account and Roic. At this time, the significance of the direction appears to have no relationship.

The correlation between Voyageur Pharmaceuticals' Free Cash Flow Per Share and Roic is 0.07. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Roic in the same time period over historical financial statements of Voyageur Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Voyageur Pharmaceuticals' Free Cash Flow Per Share and Roic is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Voyageur Pharmaceuticals are associated (or correlated) with its Roic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roic has no effect on the direction of Free Cash Flow Per Share i.e., Voyageur Pharmaceuticals' Free Cash Flow Per Share and Roic go up and down completely randomly.

Correlation Coefficient

0.07

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Most indicators from Voyageur Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Voyageur Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Voyageur Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 11.97 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 1.2 M in 2024.

Voyageur Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Retained Earnings	Other Stockholder Equity	Other Current Liab	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Assets	Inventory	Other Current Assets	Common Stock	Property Plant Equipment	Other Liab	Non Current Liabilities Total	Short Long Term Debt Total	Current Deferred Revenue
Total Assets		0.76	0.93	0.1	-0.03	-0.03	0.48	0.95	0.7	0.15	-0.94	0.92	0.68	0.94	0.38	0.31	0.92	0.78	0.4	0.51	0.94	0.91	-0.87	-0.88	-0.04	0.89
Total Current Liabilities	0.76		0.5	0.45	-0.28	-0.28	0.67	0.72	0.97	-0.08	-0.7	0.55	0.48	0.59	0.57	0.66	0.84	0.92	0.19	0.59	0.63	0.89	-0.82	-0.76	0.47	0.85
Total Stockholder Equity	0.93	0.5		-0.15	0.16	0.16	0.24	0.87	0.4	0.3	-0.89	0.93	0.58	0.95	0.24	0.1	0.82	0.52	0.53	0.38	0.91	0.79	-0.77	-0.83	-0.28	0.76
Net Debt	0.1	0.45	-0.15		-0.96	-0.96	0.26	0.31	0.47	-0.88	-0.25	0.13	0.46	0.13	-0.02	0.1	0.28	0.5	0.07	0.31	0.23	0.25	-0.31	-0.23	0.43	0.33
Cash	-0.03	-0.28	0.16	-0.96		1.0	-0.14	-0.27	-0.31	0.95	0.23	-0.13	-0.53	-0.13	0.17	0.11	-0.21	-0.37	-0.01	-0.3	-0.22	-0.15	0.16	0.12	-0.19	-0.18
Cash And Short Term Investments	-0.03	-0.28	0.16	-0.96	1.0		-0.14	-0.27	-0.31	0.95	0.23	-0.13	-0.53	-0.13	0.17	0.11	-0.21	-0.37	-0.01	-0.3	-0.22	-0.15	0.16	0.12	-0.19	-0.18
Net Receivables	0.48	0.67	0.24	0.26	-0.14	-0.14		0.36	0.75	0.12	-0.29	0.15	0.3	0.28	0.41	0.57	0.46	0.74	-0.14	0.7	0.27	0.52	-0.48	-0.33	0.26	0.52
Common Stock Shares Outstanding	0.95	0.72	0.87	0.31	-0.27	-0.27	0.36		0.66	-0.13	-0.98	0.96	0.82	0.95	0.2	0.14	0.92	0.77	0.4	0.46	0.99	0.88	-0.84	-0.85	-0.06	0.85
Total Liab	0.7	0.97	0.4	0.47	-0.31	-0.31	0.75	0.66		-0.12	-0.63	0.46	0.52	0.51	0.55	0.67	0.78	0.94	-0.01	0.56	0.56	0.83	-0.71	-0.61	0.45	0.76
Total Current Assets	0.15	-0.08	0.3	-0.88	0.95	0.95	0.12	-0.13	-0.12		0.11	-0.04	-0.44	0.01	0.32	0.28	-0.04	-0.17	0.06	0.01	-0.1	0.03	-0.03	-0.07	-0.14	0.01
Retained Earnings	-0.94	-0.7	-0.89	-0.25	0.23	0.23	-0.29	-0.98	-0.63	0.11		-0.96	-0.8	-0.96	-0.24	-0.14	-0.94	-0.72	-0.42	-0.44	-0.98	-0.9	0.82	0.85	0.12	-0.83
Other Stockholder Equity	0.92	0.55	0.93	0.13	-0.13	-0.13	0.15	0.96	0.46	-0.04	-0.96		0.75	0.97	0.12	-0.01	0.86	0.59	0.51	0.33	0.98	0.8	-0.77	-0.83	-0.21	0.77
Other Current Liab	0.68	0.48	0.58	0.46	-0.53	-0.53	0.3	0.82	0.52	-0.44	-0.8	0.75		0.74	-0.04	-0.1	0.71	0.61	-0.02	0.45	0.82	0.63	-0.45	-0.45	-0.34	0.48
Net Tangible Assets	0.94	0.59	0.95	0.13	-0.13	-0.13	0.28	0.95	0.51	0.01	-0.96	0.97	0.74		0.22	0.08	0.89	0.67	0.51	0.44	0.97	0.84	-0.81	-0.85	-0.23	0.81
Property Plant And Equipment Net	0.38	0.57	0.24	-0.02	0.17	0.17	0.41	0.2	0.55	0.32	-0.24	0.12	-0.04	0.22		0.94	0.4	0.55	0.1	0.29	0.14	0.51	-0.49	-0.44	0.38	0.51
Accounts Payable	0.31	0.66	0.1	0.1	0.11	0.11	0.57	0.14	0.67	0.28	-0.14	-0.01	-0.1	0.08	0.94		0.34	0.59	-0.02	0.35	0.04	0.47	-0.46	-0.38	0.59	0.49
Non Current Assets Total	0.92	0.84	0.82	0.28	-0.21	-0.21	0.46	0.92	0.78	-0.04	-0.94	0.86	0.71	0.89	0.4	0.34		0.82	0.38	0.53	0.89	0.99	-0.86	-0.85	0.04	0.88
Other Assets	0.78	0.92	0.52	0.5	-0.37	-0.37	0.74	0.77	0.94	-0.17	-0.72	0.59	0.61	0.67	0.55	0.59	0.82		0.13	0.56	0.68	0.86	-0.8	-0.7	0.31	0.84
Inventory	0.4	0.19	0.53	0.07	-0.01	-0.01	-0.14	0.4	-0.01	0.06	-0.42	0.51	-0.02	0.51	0.1	-0.02	0.38	0.13		0.05	0.44	0.36	-0.66	-0.7	0.19	0.6
Other Current Assets	0.51	0.59	0.38	0.31	-0.3	-0.3	0.7	0.46	0.56	0.01	-0.44	0.33	0.45	0.44	0.29	0.35	0.53	0.56	0.05		0.43	0.53	-0.46	-0.51	-0.03	0.48
Common Stock	0.94	0.63	0.91	0.23	-0.22	-0.22	0.27	0.99	0.56	-0.1	-0.98	0.98	0.82	0.97	0.14	0.04	0.89	0.68	0.44	0.43		0.84	-0.8	-0.83	-0.18	0.8
Property Plant Equipment	0.91	0.89	0.79	0.25	-0.15	-0.15	0.52	0.88	0.83	0.03	-0.9	0.8	0.63	0.84	0.51	0.47	0.99	0.86	0.36	0.53	0.84		-0.88	-0.86	0.13	0.9
Other Liab	-0.87	-0.82	-0.77	-0.31	0.16	0.16	-0.48	-0.84	-0.71	-0.03	0.82	-0.77	-0.45	-0.81	-0.49	-0.46	-0.86	-0.8	-0.66	-0.46	-0.8	-0.88		0.96	-0.34	-1.0
Non Current Liabilities Total	-0.88	-0.76	-0.83	-0.23	0.12	0.12	-0.33	-0.85	-0.61	-0.07	0.85	-0.83	-0.45	-0.85	-0.44	-0.38	-0.85	-0.7	-0.7	-0.51	-0.83	-0.86	0.96		-0.21	-0.95
Short Long Term Debt Total	-0.04	0.47	-0.28	0.43	-0.19	-0.19	0.26	-0.06	0.45	-0.14	0.12	-0.21	-0.34	-0.23	0.38	0.59	0.04	0.31	0.19	-0.03	-0.18	0.13	-0.34	-0.21		0.35
Current Deferred Revenue	0.89	0.85	0.76	0.33	-0.18	-0.18	0.52	0.85	0.76	0.01	-0.83	0.77	0.48	0.81	0.51	0.49	0.88	0.84	0.6	0.48	0.8	0.9	-1.0	-0.95	0.35

Click cells to compare fundamentals

Voyageur Pharmaceuticals Account Relationship Matchups

Voyageur Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3M	2.6M	2.1M	2.2M	2.5M	2.6M
Total Current Liabilities	910.3K	621.1K	591.3K	673.9K	775.0K	418.5K
Total Stockholder Equity	306.3K	1.9M	1.5M	1.4M	1.7M	1.7M
Net Debt	265.4K	(770.9K)	(6.0K)	37.9K	43.6K	45.8K
Cash	3.0K	813.0K	31.6K	2.1K	1.9K	1.8K
Cash And Short Term Investments	3.0K	813.0K	31.6K	2.1K	1.9K	1.8K
Net Receivables	12.7K	41.5K	23.9K	35.9K	41.3K	35.5K
Common Stock Shares Outstanding	70.5M	94.7M	107.8M	130.5M	150.1M	157.6M
Liabilities And Stockholders Equity	1.3M	2.6M	2.1M	2.2M	2.5M	2.6M
Total Liab	968.8K	660.6K	630.8K	727.9K	837.1K	484.9K
Total Current Assets	25.5K	887.3K	157.2K	88.6K	101.9K	96.8K
Retained Earnings	(3.9M)	(6.0M)	(7.7M)	(9.1M)	(8.2M)	(7.8M)
Other Stockholder Equity	791.1K	1.6M	1.6M	1.9M	2.1M	2.2M
Other Current Liab	49.1K	24.0K	1.0	673.7K	774.7K	813.4K
Net Tangible Assets	515.7K	754.1K	306.3K	1.9M	2.2M	2.3M
Property Plant And Equipment Net	1.2M	1.7M	1.9M	5.8K	6.7K	6.4K
Accounts Payable	662.4K	584.7K	591.3K	218.01	250.71	238.18
Non Current Assets Total	1.2M	1.7M	1.9M	2.1M	2.4M	1.3M
Other Current Assets	12.67	23.1K	91.4K	76.2K	87.7K	61.2K
Common Stock	3.4M	6.3M	7.6M	8.7M	10.0M	10.5M
Property Plant Equipment	1.0M	1.2M	1.2M	1.7M	1.9M	974.4K
Non Current Liabilities Total	38.1K	58.5K	39.5K	54K	48.6K	46.2K
Short Long Term Debt Total	268.4K	42.1K	25.5K	40K	36K	34.2K
Net Invested Capital	545.3K	1.9M	1.5M	1.5M	1.7M	1.1M
Net Working Capital	(884.8K)	266.2K	(434.1K)	(585.2K)	(673.0K)	(706.7K)
Short Term Debt	8.6K	114.5K	223.9K	16.6K	19.0K	18.1K
Capital Stock	3.4M	6.3M	7.6M	8.7M	10.0M	5.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Voyageur Stock Analysis

When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC